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LIST OF ABBREVIATIONS
ASA - American society of anaesthesiologist
VAS - Visual analog scale
R - Ropivacaine
RD - Ropivacaine and Dexmedetomidine
MAC - monitored anesthesia care
µg - microgram
mg - milligram
ml - milliliter
ng - nanogram
Cm - Minimum blocking concentration
min - minutes
DOS - Duration of surgery
DOA - Duration of Analgesia
On. sen  - onset of sensory block
On. mot  - Onset of motor block
Do. Sen  - Duration of sensory block
Do. Mot  - Duration of motor
Res. An  - Rescue Analgesia
Sed. Scores - Sedeation Scores
S/E - Side Effects
ABSTRACT
Background and objectives: Evaluated the effect of adding
dexmeditomidine 50µg to ropivacaine 0.5% for supraclavicular brachial
plexus block. The primary end points were the onset and the duration of
sensory and motor block and duration of analgesia.
Methods: 50 ASA I and II patients scheduled for elective mid
humerus, forearm, hand surgery were divided into 2 equal groups in a
randomized double blind fashion. In group R (n=25), 30ml of 0.5%
ropivacaine +1 ml saline and in group RD (n=25), 30ml of 0.5%
ropivacaine +1ml (½ml of dexmeditomidine 50µg mix with 1/2ml of
saline) were given. Onset time of sensory and motor block, duration of
sensory and motor block and duration of analgesia were recorded.
Results: Demographic parameters were comparable in both
groups. Onset time of Sensory and motor block were shorter in group RD
than in group R (P=0.001). Duration of Sensory and motor blockade were
longer in group RD than in group R (P=0.001). Duration of analgesia was
longer in group RD than in group R (P=0.001). Systolic blood pressure
levels in group RD at 15, 30, 45, 60, 90, 120, 180, 240, 300 minutes were
significantly lower than those in group R (P=0.001). Diastolic blood
pressure levels in group RD at 15, 30, 45, 60, 90, 120, 180, 240, 300
minutes were significantly lower than those in group R (P=0.001). Heart
rate levels in group RD except basal measurements were significantly
lower than those in group R (P=0.001).
Conclusions: Dexmedetomidine when added to ropivacaine for
brachial plexus block shortens the onset time and prolongs the duration of
the block and the duration of postoperative analgesia.
Key words: Dexmedetomidine, Ropivacaine, Ultrasound,
Supraclavicular Brachial Plexus Block
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1INTRODUCTION23, 32.
Brachial plexus blockade by supraclavicular approach is rapid onset
and complete and predictable anaesthesia for mid humerus, forearm and hand
surgery. This approach is also known as spinal anaesthesia of the upper limb
because of its common application for upper limb surgical procedures. The
anatomic characteristics are the key factor its high success rate. The compact
structure of the plexus is an added advantage to nerve block at this level.
Peripheral nerve blocks provide good operating conditions when it
used optimally. They not only provide excellent intra operative anaesthesia
but also good post-operative analgesia. They cause the least interference with
the vital physiological functions of the body, reduction in stress response,
systemic analgesia requirements, avoiding polypharmacy, opioid related side
effects and general anaesthesia requirements.
Regional blocks have traditionally been performed by eliciting
paraesthesia, anatomical landmarks and fascia clicks. Serious complication
like pneumothorax occurs due to blind technique because it is mainly
dependent on anatomical landmarks. Over the last two decades Neuro
stimulation was the Gold standard technique for nerve identification in
regional blocks. But it does not ensure the required level of nerve block. It
also causes damages to the nerve structures by direct puncture.
Ultrasound visualisation of anatomical structures facilitates safe
methods for regional blocks. This technique enables the anaesthetist to secure
2an optimal needle positioning and to monitor the distribution of local
anaesthetics in real time. The amount of local anaesthetic required for
effective nerve block can be minimised by directly monitoring its
distribution.  Local anaesthetic blocks the nerve but is not blocked by the
needle.
Most of the local anaesthetic agents developed in the first half of 20th
century (1900-1940) were basically amino ester compounds. They lost their
importance due to their shorter duration of action and associated allergic
reactions and systemic side effects. This paved the way for synthesis of
newer agents namely the amino amide compounds such as bupivacaine,
levobupivacaine, ropivacaine etc.
Ropivacaine is considered to be superior over bupivacaine, as it
provides more differential block when given via epidural route. Motor block
is not preferable during epidural labour and postoperative analgesia. In these
situations ropivacaine offers greater sensory and motor separation.
Ropivacaine is less cardiovascular and central nervous system toxicity than
bupivacaine. The decreased systemic toxicity is better when a potential for
high concentrations of local anaesthetic agents are used in peripheral nerve
block and epidural anaesthesia. Because of its advantages, ropivacaine may
be a better choice to bupivacaine.
To prolong the duration of analgesia various drugs have been studied
as adjuvants to local anaesthetic solution and techniques such as the
continuous catheter placement in the brachial plexus have evolved. These
3adjuvant drugs added to peripheral nerve block are expected to enhance the
duration of analgesia without causing any systemic adverse effects and
prolonging motor blockade. Novel ?-2 adrenergic agent, Dexmeditomidine is
eight times more selective for ?-2 adrenoreceptor than clonidine. It has an
analgesic, sedative and good cardiovascular stabilizing effect.
The present study was designed to compare between ropivacaine and
ropivacaine with dexmeditomidine in ultrasound guidance supraclavicular
brachial plexus block scheduled for upper limb orthopaedic surgery.
4HISTORY21
Regional anesthesia traces its origin to Dr. Karl Koller a young
Austrian ophthalmologist, who in 1884 instilled a cocaine solution into his
own eye, tested its effectiveness and employed for topical corneal anesthesia
in patients undergoing eye surgeries.
The first brachial plexus block was performed by William
Halsted in1889. He directly exposed the brachial plexus in the neck to
perform the block and he used cocaine.
Harvey Cushing, a Halsted's surgical residents who applied cocaine to
the brachial plexus during a forequarter amputation for sarcoma in the year
1900.
German surgeon named Diedrich Kulenkampff performed the
first percutaneous supraclavicular block in 1911. He subjected himself to the
supraclavicular brachial block.
Percutaneous approach to the brachial plexus from the axilla was first
described by Georg Hirschel.
Kulenkampff first described classical supraclavicular approach to
brachial plexus. With numerous blocks performed by Kulenkampff and his
colleuge Persky and published their experiences without apparent major
complications.
5Continuous brachial plexus block technique was first described by F.
Paul Ansbro in 1946. He followed a method of securing a needle in the
supraclavicular fossa where he attached a tube connected with a syringe
through which local anesthetic drugs are injected. The axillary approach was
first performed by Accardo and Adriano in 1949.
The subclavian perivascular method was first described by Winnie and
Collins in 1964 and it became popular due to its decreased risk of
complication like pneumothorax when compared to the traditional
Kulenkampff approach.
Raj first developed the infraclavicular approach. A technique for
continuous brachial plexus block by using an intravenous catheter in the
axilla was described by Selander in 1977.
The use of ultrasound for nerve blocks was first reported by P. La
Grange and his colleagues in 1978.He performed supraclavicular brachial
plexus blocks with the help of a Doppler blood flow detector and reported
high success rate without complications.
B - Mode ultrasonography was used to demonstrate the anatomical
structure of axilla and spread of local anesthetics in axillary brachial plexus
block was reported by P. Ting and V. Sivagnanaratnam in 1989.
6Stephan Kapral et al in 1994 published the first reported use of direct
sonographic visualization for regional anesthesia. Over the past ten years
however dramatic progress has been made.
7AIM OF THE STUDY
The aim of the present study was to evaluate the clinical effectiveness,
block quality and hemodynamic effects when addition of Dexmedetomidine
50µg to 0.5% Ropivacaine in ultrasound supraclavicular brachial plexus
block. The following parameters were observed.
? Onset of sensory and motor blockade.
? Duration of sensory and motor blockade.
? Duration of Analgesia.
? Hemodynamic changes.
? Sedation.
? Time of Rescue analgesia.
? Complications.
8BRACHIAL PLEXUS 28, 29, 30
Brachial plexus block is one of the most commonly used peripheral
nerve blocks in clinical practice. Hence the knowledge of the brachial plexus
and of its distribution is absolutely essential for the effective blockade.
Mastery of various techniques of brachial plexus anesthesia purely depends
on familiarity with the vascular, muscular and fascial relationship of the
brachial plexus throughout its formation and distribution.
In its course from the intervertebral foramina to the upper arm, the
fibers that constitute the plexus are composed consecutively of roots, trunks,
cords, divisions and terminal nerves which are formed through a complex
process of combining, dividing, recombining and finally re-dividing.
Formation of the plexus
Roots
The brachial plexus is formed by the union of anterior primary rami of
fifth to eighth cervical nerve and first thoracic nerve with occasional
contributions from the fourth cervical nerve (prefixed) above and second
thoracic nerve (post fixed) below. These nerves unite to form trunks, which
lie in the neck above the clavicle. The discrepancies are commonly related
with the occurrence of a cervical rib, anomalous of first rib.
9Brachial plexus
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Trunks
The emergence of five roots of the brachial plexus is from the
intervertebral foramina. They lie in the gutter between the anterior and
posterior tubercles of the corresponding transverse process. All five roots
then become sandwiched between scalenus anterior and scalenus medius.
Here  the  roots  of  C5 and C6 unite into the upper trunk, the root of C7
continues as the middle trunk and those of C8 and  T1 into the lower trunk.
Each trunk divides behind the clavicle, into anterior and posterior divisions
which unite in the axilla to form cords.
Cords
Three cords are formed when the six divisions, stream into the axilla and
joint together. These cords are
? Lateral
? Medial
? Posterior
The union of the anterior divisions of the upper and middle trunks
forms the lateral cord. The medial cord represents the continuation of the
anterior division of the lower trunk. The posterior cord comprises of the
posterior divisions of all the three trunks.
12
 The composition of brachial plexus can be summarized as follows:
1. Five roots (between the scalene muscles) - the anterior primary rami
of C5 - C8 and T1
2. Three trunks (in the posterior triangle)
a) Upper trunk - C5 and C6
b) Middle trunk - C7 alone
c) Lower trunk - C8 and T1
3. Six divisions (behind the clavicle) - each trunk divides into an
anterior and posterior division.
4. Three cords (within the axilla)
a) Lateral cord-the fused anterior division of the upper and middle
trunks C5-C7.
b) Medial cord - the anterior division of the lower trunk C8-T1
c) Posterior cord- formed by the union of the posterior divisions of
all three trunks C5 – T1.
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Branches
Branches are given off from roots, trunks, and cords.
1. Branches from the roots:
a) Nerve to the serratus anterior (C5, C6, and C7)
b) Muscular branches to
- Longus cervices (C5-C8)
- Scalene muscles (C5-C8)
- Nerve to rhomboids (C5)
- Scalene muscles (C5-C8)
- Contribution to phrenic nerve
2. Branches from the trunks:
a) Suprascapular nerve (C5-C6)
b) Nerve to subclavius (C5-C6)
3. Branches from the cords:
a) Lateral cord
- Lateral pectoral nerve (C5-C7)
- Lateral head of median nerve (C5-C7)
14
- Musculocutaneous nerve (C5-C7)
b) Medial cord
- Medial pectoral nerve (C8-T1)
- Medial head of median nerve (C8-T1)
- Medial Cutaneous nerve of arm (C8-T1)
- Medial cutaneous nerve of forearm (C8-T1)
- Ulnar nerve (C7, C8-T1)
c) Posterior cord
- Upper subscapular nerve (C5- C6)
- Lower subscapular nerve (C5-C6)
- Nerve to latissimus dorsi (C6, C7, C8)
- Axillary nerve (C5-C6)
- Radial nerve (C5, C6, C7, C8 T1)
Relations of the brachial plexus
Its roots pass through the fascia enclosed space between the scalenus
anterior and the scalenus medius accompanied by subclavian artery and
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invaginate the scalene fascia to form a neurovascular bundle. This fascia
becomes axillary sheath in the axilla.
Trunks
The trunks of the plexus are enclosed in a sheath of prevertebral fascia
in the posterior triangle. These trunks of brachial plexus are placed
superficially and it is covered by the skin, platysma and deep fascia.
The upper and middle trunks when they stream across the first rib subclavian
artery runs above, whereas the lower trunk which found behind the artery
immediately posterior to the subclavian groove, may ridge the rib.
Division
The trunks splits into divisions at the lateral border of first rib which
are present behind the three structures namely clavicle, the suprascapular
vessels and subclavius muscle.
Cords
At the apex of axilla the cords are moulded and they segregate around
the axillary artery.
The interscalene sheath
Roots of the brachial plexus originate in a trench between the two
tubercles of the transverse process of the cervical vertebrae and situated in
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between two strands of fibrous fatty tissue space. Anterior and Posterior part
of the sheath arises from the corresponding tubercles of cervical vertebrae.
The front of the scalenus medius is covered by posterior part of sheath
whereas posterior part of scalenus anterior is covered by anterior part of
sheath.
Importance to Anesthetist
The interscalene sheath surrounding the brachial plexus along which
local anesthetic solution may be injected to achieve brachial plexus block. It
can be performed by interscalene or axillary approach.
17
Brachial Plexus - Branches
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Anatomic considerations
The prevertebral and scalene fascia surrounds the brachial plexus.
Fascial sheath constitutes prevertebral fascia and scalene fascia which
extends from the intervertebral foramina to the upper arm. The existence of
the facial sheath renders brachial plexus block easier. The sheath can be
injected at any anatomical level that allows easy distribution of local
anesthetic drugs and subsequent blockade of brachial plexus.
Brachial plexus blockade offers anesthesia of upper extremity surgical
procedures. Brachial plexus are blocked by four techniques. They are
?  Interscalene
? Supraclavicular
? Infraclavicular
? Axillary approach
The technique to be used in any case should be determined on the basis
of surgical site, the required level of anesthesia, physical status and habitus of
the patient.
Each technique has a chance of missing a nerve distribution that needs
additional supplementation. The upper median aspect of the arm is not
anaesthetised by any brachial plexus technique. This area innervated by the
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medial brachial cutaneous nerve (C8-T1) and intercostobrachial nerve (T2)
which are not a part of the brachial plexus sheath. This nerve can be blocked
by subcutaneous infiltration across the upper medial aspect of the arm using
3-5ml of local anesthesia solution to prevent tourniquet pain.
A part of the anterior shoulder is innervated by the superficial cervical
plexus (C1-C4). This is effectively blocked by subcutaneous infiltration along
the posterior border of the sternocleomastoid during a shoulder surgery.
Brachial plexus can be blocked at the level of roots, trunks, cords or
peripheral branches. The block at each level has a distinct distribution of
anesthesia, advantages, disadvantages and complications.
20
APPLIED PHYSIOLOGY24
Physiology of Nerve Conduction32
Neurons are the basic building blocks of the nervous system that
respond to various stimuli. Integration and transmission of nerve impulses are
specialized functions of neurons.
All peripheral nerves are elongated axons of neurons situated centrally.
A typical peripheral nerve consists of bundles of motor, sensory and other
fibres enclosed in the outermost covering called epineurium. Inside the
epineurium, the perineurium surrounds the collection of bundles. Each bundle
is surrounded by an endoneurium. Each nerve fibre in a bundle in layer of
neurilemma or the axonal membrane. Depending on the presence or absence
of myelin sheath, it can be a myelinated nerve fibre or unmyelinated nerve
fibre.
The axonal membrane itself is made up of a bimolecular lipid palisade,
interspersed with large protein molecules. The membrane lipids are largely
phospholipids composed of a polar head group and a non-polar hydrocarbon
tail.
The primary function of the cell membrane is to separate the
extracellular from the intracellular environment. The major difference
between these two environments is the ionic concentration. This
disequilibrium provides the means for impulse conduction.
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The most important ions in the respect are sodium and potassium. A
membrane bound protein sodium potassium ATPase maintains normal resting
equilibrium potential between - 50 mv to - 90 mv by pumping sodium ions
out of the cell and potassium ions into the cell. A positive ion gradient from
inside the membrane to the outside causes electro negativity inside the
membrane. During nerve conduction the following changes occur in the cell
membrane.
Resting phase
There is a potential difference across the membrane inside is negative,
due to a higher concentration of Na+ outside than the inside the cell. K+
moves  out  of  the  cells  and  Na+ moves in but because of more K+ channels
opened at rest, K+ permeability is greater than Na+ permeability. Therefore
K+ channels maintain the resting membrane potential.
Depolarization phase
During excitation, Na+ channels in the cell membrane open briefly
allowing Na+ to flow into the cell, thereby depolarizing the membrane.
Repolarization phase
During this phase, opening of voltage gated K+ channels occurs, results
in passing of K+ to the cell to restore electrical neutrality.
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Restoration phase
During this phase, Na+ returns to the outside and K+ re-enter the cell.
Distribution of ion channels in myelinated neurons
Voltage gated Na+ channels are highly concentrated in the Nodes of
Ranvier and the initial segment in the myelinated neurons. The initial
segment and in sensory neurons, the first node of Ranvier are the sites where
the impulses are normally generated and the other nodes of Ranvier are the
sites to which the impulses jump during salutatory conduction.
The Na+ channel is believed to be an integral membrane spanning
protein. The three dimensional configuration of the proteins forms a pore
through the neuronal membrane. Depolarization of the cell induces a
configurational change on the Na+ channel which causes it to open and allow
ion passage. In many myelinated neurons, the Na+ channels are flanked by K+
channels that are involved in repolarization.
23
Nodes of Ranvier
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Nerve Fibers21
Nerve fibers are classified into A, B, and C fibers. A- Fibers is further
divided into ?, ?, ? and ? fibers. A- Fibers are myelinated somatic nerves, B -
Fibers are myelinated preganglionic autonomic nerves and C - Fibers are
unmyelinated nerves. The susceptibility of nerves to local anesthetics
depends on their caliber, degree of myelination, speed of conduction.
Characteristics of different categories of nerve fiber
Characteristics ?? A? A? A? B C
Diameter (?m) 12-20 5-12 5-12 1-4 1-3 0.5-1
Conduction
Speed
70-
120
30-70 30-70 12-
30
14-8 12
Myelination +++ ++ ++ + + -
Function Motor Pressure
touch
Proprioception Pain
temp
Vaso
constriction
Pain
temp.
Onset of block 5th 4th 3rd 2nd 1st 2nd
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Differential nerve block
Within a single peripheral nerve, the complete block of pain fibers (A?
and C) and sparing of motor and touch (A? and A?) is known as differential
block. This is may be due to
1. Time taken for a drug to diffuse into and along the course of nerve to
affect various fibers.
2. The presence or absence of a myelin sheath may affect local anesthetic
activity and penetration.
3. Not all axons have the same sensitivity to local anesthetic agents
because of variations in Na+ channel and membrane lipid content.
Nerve Penetration
The fibers innervating the distal portions of a limb are in the center of
the nerve trunk. The more proximal structures are supplied from the outer
layers of the trunk. Following deposition of the drug, the more proximal limb
structures anesthetized before the distal ones.
? Proximal - early block
? Distal - delayed block
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Regression of the block is primarily dependent on diffusion from the nerve
and absorption into the local vasculature. Drugs with high lipophilic
solubility diffuse slowly from local tissues.
Minimum blocking concentration (Cm)
It is the lowest concentration of local anesthetic agent that will block
conduction in a nerve in vitro. In vivo, the drug is injected in and about nerve
trunks, fibrous sheaths, fatty tissue and blood vessels. Therefore, before
reaching the nerve, it is subject to dilution, dispersion, fixation, destruction
and systemic absorption. Under these conditions, the minimum concentration
necessary to block a nerve is much greater than the Cm.
Local anesthetics action on nerve fibers24
The primary action of local anesthetics on the nerves is electrical
stabilization. The large transient increase in permeability to Na+ necessary for
propagation of the nerve impulse is prevented. Thus the resting membrane
potential is maintained and depolarization in response to stimulation is
inhibited.
Local anesthetics block sodium conductance by
? By action of local anesthetic drugs to sites on voltage gated Na+
channels limits opening of the channels by inhibiting the
conformational changes that underlie channel activation.
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? Local anesthetic drugs produce nonspecific membrane
expansion. There is an unfolding of membrane protein together
with a disordering of the lipid component of the cell membrane
with consequent obstruction of the Na+ channel.
28
ROPIVACAINE HYDROCHLORIDE25, 26, 27
Ropivacaine belongs to a long-acting amide local anaesthetic drug. It
was first synthesized as a pure enantiomer. When compared to bupivacaine it
is less lipophilic with a less chance to penetrate motor fibers which is large
and myelinated, hence it results in a decreased motor blockade. Because of
less lipophilic it leads to less cardiovascular and central nervous system side
effects than bupivacaine. The decreased systemic toxicity is better when a
potential for high concentrations of local anaesthetic agents are used in
peripheral nerve block and epidural anaesthesia.
Ropivacaine is considered to be superior over bupivacaine, as it provides
more differential block when given via epidural route. Motor block is not
preferable during epidural labour and postoperative analgesia. In these
situations ropivacaine offers greater sensory and motor separation.
It belongs to mepivacaine family. It is introduced into the market during the
year 1996.
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Chemical
It is an amide local anaesthetic (S)-N-(2, 6-dimethylphenyl)-1-
propylpiperidine-2-carboxamide.
It is a pure S (-) enantiomer.
It belongs to the pipecoloxylidide group of local anaesthetics.
It has a propyl group on the piperidine nitrogen atom. But bupivacaine
has a butyl group.
Presentation
As a clear, containing racemic ropivacaine hydrochloride monohydrate
(S - and R - enantiomers) in concentration of 0.2/0.5/0.75/1% equivalent to
2mg,5mg, 7.5 mg, 10mg/ml respectively. The preparation also contains
sodium hydroxide equivalent to 3.7mg of sodium per ml.
Physiochemical properties
Molecular weight            : 274
Pka : 8.1
Protein binding : 94%
VD : 52-66 l
Elimination T ½ : 59-173 minutes
Clearance : 0.44 – 0.82l/min
Excretion : Renal 86%
30
Routes of administration/ doses
Ropivacaine may be administered topically, by infiltration, epidurally.
Maximum recommended dose of ropivacaine is 3mg/kg. Alkalinization of
0.75% ropivacaine leads to prolongation of analgesia.
31
Mechanism of action
Local anaesthetics block the generation and conduction of nerve
impulses presumably by increasing the threshold for electrical excitation in
the nerve, by slowing the propagation of the nerve impulse, and by reducing
the rate of rise of the action potential.
In general the progression of anaesthesia is related to the diameter,
myelination and conduction velocity of nerve fibres. Clinically the order of
loss of nerve function is as follows.
32
1. Pain
2. Temperature
3. Touch
4. Proprioception
5. Skeletal muscle tone
Ropivacaine leads to reversible inhibition of sodium ion influx. Hence
it produces conduction blockade in nerve fibres. This is potentiated by
potassium channels inhibition. Because of its less lipophilicity and less likely
to penetrate large motor myelinated fibres. It has differential block due to its
selective action on the nerve fibers.
S-ropivacaine is more potent and less cardio toxic than R-ropivacaine.
Pharmacodynamics
Central nervous system
The principle effect of ropivacaine is reversible neural blockade. This
leads to a characteristically biphasic effect in the central nervous system.
During accidental over dosage or direct vascular injections the clinical signs
are numbness of tongue, light headedness, visual and auditory disturbances,
muscular twitching’s, tremors. When plasma level continues to raise central
nervous system excitation is rapidly superseded by depression, drowsiness,
disorientation and coma.
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Ropivacaine is less lipophilic than bupivacaine. Because its stereo
selectivity, it has higher threshold for cardio toxicity and Central nervous
system toxicity. The Central nervous system effects occurred earlier than
cardio toxic symptom.
Cardiovascular system
Ropivacaine is less cardio toxic than bupivacaine. In toxic
concentrations the drug decreases the peripheral vascular resistance and
myocardial contractility thereby producing hypotension and possibly
cardiovascular collapse. It has biphasic vascular effect causing
vasoconstriction at low but not at high concentrations.
Other effects
Ropivacaine does not compromise the uteroplacental circulation.
Ropivacaine inhibits platelet aggregation.
It has antibacterial activity in vitro.
Pharmacokinetics
The absorption of local anaesthetic agents is related to
? The site of injection
          (Intercostal>caudal>epidural>brachial plexus>subcutaneous)
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? The dose – a linear relationship exists between the total dose and the
peak blood concentrations achieved.
? The presence of vasoconstrictors which delay the absorption.
Distribution
Ropivacaine is 94% protein bound and predominantly binds to ?-1 acid
glycoprotein. The volume of distribution is 52-60 litres. It has biphasic
absorption profile from epidural space with half-life of 4 hours and 14
minutes in adults.
Plasma concentration of ropivacaine mainly depends on the following
factors.
1. The total dose administered and the route of administration.
2. Haemodynamic and circulatory condition of the patient.
3. Vascularity of the administration site.
During continuous epidural infusion of ropivacaine the total plasma
concentration increases due to an increase in the protein binding and decrease
in the clearance of ropivacaine.
During epidural administration for caesarean section, it rapidly crosses
the placenta which results in the equilibrium between the maternal and foetal
circulation. Due to increased concentration of ?1 - acid glycoprotein in
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maternal side than in foetal side, the amount of drug present in the maternal
circulation is more than the foetal circulation.
Metabolism
In the liver ropivacaine is metabolised by aromatic hydroxylation via
cytochrome P450 (CYP) 1A2 to 3? - hydroxyl - ropivacaine which is the
major metabolite. The isoenzyme CYP3A4 is also involved in the
metabolism of ropivacaine to 2?, 6?-pipecoloxylidide.
Excretion
Ropivacaine is mainly excreted via kidney, which is accounting for
86%, 37% of 3 – hydroxyl – ropivacaine is excreted in the urine and 1% is
unchanged. Terminal half-life is 59 – 173 minutes.
The clearance is 0.44 – 0.82 litres per minute.
Due to biphasic absorption, the elimination half – life is longer after
epidural administration (approximately 4.2 hours) than after intravenous
administration.
Side effects
Allergic responses to the amide-type of local anaesthetic agents are
extremely rare. The side effects are predominantly due to excessive plasma
concentrations of the drug. The common side effects are hypotension, nausea,
vomiting, bradycardia and headache.
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Higher incidence of cardiovascular toxicity like bradycardia, hypotension
reported in
? Age more than 60 years
? sudden IV injection
? Massive absorption from peripheral nerve blocks.
Drug interactions
Due to toxic effects of additive action, care to be taken with patients
receiving other amide – type local anaesthetics.
Co-administration of CYP1A2 inhibitors like fluvoxamine with
ropivacaine results in increased plasma concentration of ropivacaine. Other
drugs like theophylline and imipramine may also metabolised by CYP1A2
via competitive inhibition. Hence careful administration of these drugs is
needed due to its possible interaction.
Special points
The onset and duration of conduction blockade is mainly related to
? pKa
? Lipid solubility
? Extent of protein binding
A low pKa and high lipid solubility are associated with a rapid onset time.
High degree of protein binding is associated with long duration of action.
37
Clinical applications
1. Epidural administration for many surgical procedures and post-
operative analgesia.
2. Central Blocks.
3. Peripheral nerve blocks like brachial plexus, sciatic nerve block,
femoral nerve block and ankle block.
4. Labour epidural analgesia – Ropivacaine provides effective pain relief
in labour. Due to its differential blockade ropivacaine is advantageous
in labour analgesia.
5. Extradural anaesthesia for caesarean section.
6. Infiltration Anaesthesia.
7. Chronic pain management in cancer patients.
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DEXMEDETOMIDINE HYDROCHLORIDE 25, 26, 31.
It  is  highly   selective  and more  potent    and ? -   2   adrenoreceptor
agonist  with  much  greater  affinity for  ? -  2  receptors over  ?-1(1620:1).
It exerts   analgesic, sedative, anxiolytic and hemodynamic stability. Its
hemodynamic effects are due to sympatholytic action. This  novel agent
used  as  adjuvant  during  anaesthesia   to  reduce  the  hypnotic  and  opioid
requirements  for  conscious  sedation.
History
In the early 1960s the first ?2-adrenoceptor agonist was used for nasal
decongestant purpose.
The introduction of clonidine as an antihypertensive drug in 1966.
In December 1999, dexmedetomidine was approved and used in
humans for sedation, but only for a short period of time.
(S)-4-[1-(2, 3-Dimethylphenyl) ethyl]-3H-imidazole
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Chemical: An imidazole derivative.
As a clear, colourless, isotonic solution containing dexmedetomidine
base 100 µg/ml. It is preservative-free solution.
Physiochemical properties
Protein binding : 94%
Metabolism : Near complete hepatic metabolism to
inactive metabolites
VD : 118 l/kg
Distribution half-life : 6 minutes
Elimination half-life : 2 hours
Excretion : 95% of the metabolites excreted in the urine
Clearance : 39 l/hr
Route of administration/doses
ICU sedation
The drug is administered by intravenous infusion commencing at
1 µg/kg for 10 minutes, then at 0.2 – 0.7 µg/ kg/hr. The duration should not
exceed 24 hrs. It also been administered transdermally and intramuscularly.
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Main action
It has an analgesic, amnestic, sedative, anxiolytic properties.
Mechanism of action
The main action of ?–1 receptor is the regulation of vascular tone. It is
widely distributed. The ?-2 receptors are present in the peripheral as well as
in the central nervous system which are pre and post synaptic receptors.
Sedative actions are believed to be mediated primarily by post synaptic ?-2
receptors. The main action of ?-2 a receptors are sedative, anxiolytic and
sympatholytic effects. They are mediated via G-protein inhibition of L-type
calcium channels   which are present in the post - synaptic receptors located
in the locus coerelus.   It appears to inhibit ion conductance through L-or P-
type calcium channels and to facilitate conductance through voltage - gated
calcium activated potassium   channels. These effects are readily reversible
by ? -2 adrenergic antagonists like atipamezole.
Cognitive function does not alter with dexmedetomidine. When
compared to propofol and thiopentone, they cause hyperpolarization of
neurons through chloride channels opening.
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MECHANISM OF ACTION
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It produces analgesic action by an alpha–2 receptor which is present in
the spinal cord and the locus coerelus. Substance P released from the
modulation of spinal cord - dorsal horn which has more alpha – 2 receptors
thereby producing the analgesic effect.
Decreased sympathetic output centrally by stimulation of ?–2
adrenergic receptors produces more inhibitory neurons firing action.
In vascular system by Stimulation of ?-2 receptors post synaptically
produces vasoconstriction effect. Thus, dexmedetomidine has dual mode of
action ie, central and peripheral. Centrally, it acts on the post synaptic ?-2
inhibitory receptors, resulting in sympatholysis and sedation. The same action
at the peripheral level leads to analgesic effect. In the peripheral nerves and
autonomic ganglia it reduces the release of catecholamines leading to
sympatholytic effect.
Decreased systemic vascular resistance and indirectly decreased
myocardial contractility, cardiac output and systemic blood pressure. The
initial hypertensive response is because of vasoconstriction effect mediated
by peripherally located post synaptic alpha-2B action. This vasoconstriction
effect can be prevented by slow administration of initial dose. Hypotension
and bradycardia are caused by central pre-synaptic stimulation of alpha-2A
with reduced norepinephrine release.
43
Pharmacokinetics
Following intravenous administration dexmedetomidine produces rapid
distribution phase with distribution half-life about six minutes. The
elimination half - life is approximately 2 hours and a clearance of 39L/h.
Complete biotransformation involves both direct glucuronidation as well as
cytochrome P450 (primarily by CYP2A6) mediated mechanism in the hepatic
system. The metabolites do not have any clinical effects. They are excreted
predominantly in the urine and little in the feces. Dose reduction may be
needed in hepatic dysfunction. The excretion of the metabolite via the
kidneys necessitates a dose reduction only when the Creatinine Clearance is
less than 30ml per min, but half the dose reduction may be necessary with
hepatic impairment. Even with continuous infusion more than 24 hours
accumulation of drugs does not occur. Plasma concentration of therapeutic
levels ranges between 0.3 to 0.6ng/ml.
Perioperative uses of dexmedetomidine
Premedication
It possesses anxiolytic, sedative, analgesic, antisialogogue and
sympatholytic properties, which render it suitable as a premedication agent.
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Intraoperative uses
? As adjunct to general anesthesia
The use of intraoperative dexmedetomidine may increase
hemodynamic stability because of attenuation of the stress - induced
sympathoadrenal responses to intubation, during surgery and during
emergence from anesthesia.
? As adjunct to regional anesthesia
It shortened the onset time and prolonged the duration of the block and
post-operative analgesia. The peripheral analgesic effects of
dexmedetomidine that potentiate local anesthetics are mediated by ?2A-AR
binding to enhance the post-operative analgesia.
? In monitored anesthesia care (MAC)
It is a safe sedative alternative to benzodiazepine/opioid combinations
in patients undergoing monitored anesthesia care for a multitude of
procedures because of its analgesic, cooperative sedation, lack of respiratory
depression properties.
? As a sole agent for procedural sedation.
A new role as a sole agent for procedural sedation is fast emerging
mainly due to its faster onset of action, faster recovery and discharge times.
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? Post-operative
Post operatively intravenous dexmedetomidine infusion is associated
with a reduction in nausea and vomiting, reducing postoperative morbidity.
? For acute / chronic pain
The management of acute postoperative pain and chronic pain states,
neuropathic pain, muscle spasticity and myofascial pain, sympathetically
maintained pain such as complex regional pain syndrome (CRPS) and
chronic headaches are due to its effects of opiate sparing action which has
significant implications. It is evolving as an adjuvant analgesic, both as
intravenous and intrathecal infusion, in cancer pain refractory to multiple
treatment modalities.
Other uses
Prevention and treatment of emergence delirium, Alcohol withdrawal,
shivering.
Precautions
Caution when used in patients with severe bradycardia, severe
ventricular dysfunction (EF<30%), cardiac failure. Continuous blood
pressure, electrocardiogram and oxygen saturation are recommended during
infusion.
Toxicity
Hypotension, Hypertension, bradycardia, nausea, dry mouth.
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ULTRASOUND GUIDANCE IN REGIONAL ANAESTHESIA20, 21, 22.
Supraclavicular plexus block was originally described by Kulenkampff
in 1911. He introduced the concept of locating a nerve with paresthesia.
Serious complication like pneumothorax due to blind technique because it
mainly dependent on the anatomical landmarks. With advent of ultrasound
supraclavicular block has become the most popular and common technique to
provide   anesthesia and analgesia to upper limb surgical procedures.
Non- invasive visualization of tissue structures by ultrasound
technique, ensures the optimal spread of local anesthetic solutions around
nerve structures. It hence improves the quality of analgesia and avoids the
complication like inadvertent, intraneuronal and intravascular injection.
Principles
Ultrasound is a mechanical wave with frequencies over 20000 Hz
sound   generated and sent through tissues. Penetration into tissue is based in
large part on the range of the frequency produced. Lower frequencies 2 MHz
penetrate deeper than higher frequencies 10 MHz. As the sound passes
through tissues it is either absorbed, reflected or allowed to pass through
depending on the   echodensity of the tissue. All ultrasound waves dissipate
in tissues producing heat.
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High frequency linear probe (8-15 MHZ)
48
Sonographic appearance of supraclavicular brachial plexus
(Bundle of hypo - echoic round nodules)
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The listening part of the probe (a piezo electric crystal) like the
generating part of the probe listens for reflections of the sound waves sent out
and passes information to the processing unit.
The amount of energy reflected which is not absorbed or propagated
equals density. Substances with a high water content like CSF and blood are
very   good conductors of sound. They reflect very poorly and are called
echoluscent. Because they reflect very little of the sound, they appear as dark
areas.  Substances with low in water cotent like air, bone are poor sound
conductors   reflect all the sound energy and appear very bright. Substances
which conduct sound between these two extremes appear darker to lighter
depending on the amount of energy they reflect.
Ultrasound machine
The echoes received by the transducer are converted into visible dots
by the ultrasound machine which helps in the formation of the anatomic
image on the ultrasound screen. The ultrasound machines that are currently
been used in the regional anesthesia provide a 2-D image. Recent advance of
machine with 3- D image system are developed. It provides better
visualization of local anesthetics solution distribution around the plexus and
the identification of anatomical structures.
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It consists of a transducer, control unit and display.
Transducers vary in size, shape, frequency range and number of
piezoelectric crystals. For superficial block, high frequency transducer (7-
15MHz) will provide better axial resolution. The presence of more
piezoelectric crystal elements, produce the better the resolution. A lower
frequency transducer (1- 5MHz) is appropriate  for deeper blocks as there is
less absorption and thus better signal from the deeper structure. Transducers
with a small footprint (i.e. hockey stick transducers) are useful in children or
where space is limiting. Wider with large footprint and curvilinear transducer
allow for visualization of a bigger with large area. An aqueous gel is used as
a coupling medium that is applied between the skin and the transducer for the
elimination of the air layer.
Control unit allows for adjusting the depth of image, gain, focus to
select different visualization modes etc. The ultrasound transducer
incorporates a battery of piezoelectric crystals. When scanning the transducer
switches quickly between transmitter and receiver mode. When in
transmitting mode the piezoelectric crystals are stimulated by electrical
energy vibrate and emit ultrasound waves. In the receiver mode the crystals
are hit by the ultrasound waves reflected from the tissues. Finally, the
mechanical stimulation of crystals is converted to electrical signals, which are
processed and ultimately create the image we see on the screen.
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Selecting the appropriate depth is the first step while scanning. The
target structure should be in the center of the imaging field where the best
resolution is possible. By manipulating the gain one can improve the image
quality. The focus refers to the depth at which best lateral resolution is
achieved.
Two needle insertion technique
The needle can be inserted in two ways. They are:
? In-plane technique
? Out-of-plane technique
In the first technique needle is to be kept in the plane of ultrasound
beam, which results in the clear longitudinal view of the tip and needle shaft
when it is advanced towards the target nerve.
In the next technique the needle must be inserted perpendicular to the
transducer. The shaft of the needle is observed in a cross - section plane and a
bright dot in the image can be seen. When compared to in-plane technique
the needle tip is difficult to visualize and is not reliable in this method.
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Sonographic appearance of peripheral nerves and various structures
The peripheral nerves appear hypo echoic (dark structures) or hyper
echoic (bright structures) depends on
a) The size of the nerve
                           b) Sonographic frequency
                           c) Angle of ultrasound beam
The proximal parts i.e. nerve roots when scanning the interscalene area
are rich in nerve tissue and appear black or hypo echoic. As the brachial
plexus runs distally i.e. supraclavicular area, the proportion of connective
tissue increases    and the nerve has a grape like appearance. Further distally
in the upper limb the connective tissue dominates and nerves appear more
hyper echoic (honey comb appearance). Blood vessels can be identified by
using Doppler colour ultra sound.
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REVIEW OF LITERATURE
1. M.S. Abrahams, M.F. Aziz et al (2009)1 did a systematic review and
meta-analysis of randomized controlled trials in ultrasound guided
peripheral nerve block versus electrical neurostimulation method. They
concluded that ultra sound improves the effectiveness of peripheral
nerve blockade when compared to neurolocator for the identification of
nerve.
2.  Vincent W.S. Chan, Anahi Perlas et al(2007)2 conducted a study in 188
patients using ultrasound guided(US), nerve stimulator(NS) and
combined both (USNS). They proved that axillary brachial plexus
block can be significantly improved by the guidance of ultrasound with
or without concomitant use of nerve stimulation.
3. Vincent W.S. Chan, Anahi Perlas et al (2003)3 40 outpatients were
assessed based on the ultrasound technology for supraclavicular
brachial plexus blocks. Brachial plexus was identified using the
ultrasound imaging technique. It also helps to guide the block needle to
reach the target nerves and in the visualization of the pattern of local
anaesthetic distribution. The block was successful after one attempt in
95% cases with one failure due to subcutaneous injection. There was
no pneumothorax. They suggested that ultrasound probe with a high
55
resolution can accurately localise the brachial plexus and the structures
near it in the supraclavicular region for peripheral nerve blockade.
4. Tomki Nishiyama, Higashi Omiya et al (2012)4 compared the motor
and sensory block by ropivacaine and bupivacaine in combination with
lidocaine in 100 adult patients scheduled for repair of fracture of the
upper extremity under interscalene block. They found that interscalene
block combined with lidocaine, ropivacaine had slower onset of motor
block and longer duration of both sensory and motor blocks than
bupivacaine.
5. Esmaoglu A, Yegenoglu F, et al(2010)5 added dexmedetomidine to
levobupivacaine for axillary brachial plexus block and found that it
shortens the  time of onset in both sensorimotor block and prolonged
the duration of block and duration of postoperative analgesia. Because
it reduces the release of norepinephrine, leading to ?-2 receptor
independent inhibitory effects on nerve fibre action potentials.
6.  Brummet   CM,  Hong  EK,  Janda  AM,  et  al  (  2011)7 showed that
perineural   dexmeditomidine added to ropivacaine for sciatic nerve
block in rats   prolonged the duration of analgesia by blocking the
hyperpolarisation-  activated  cation current, which prevents the nerve
from returning from a   hyperpolarised state to resting membrane
potential for subsequent firing.
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7. Hickey, Hoffman J, Ramamurthy S,(1991) compared the effectiveness
of 0.5% ropivacaine and 0.5% bupivacaine in 48 patients received a
subclavian  perivascular brachial plexus block for upper extremity
surgery and concluded that both the drugs were equally effective in
providing brachial anaesthesia.
8. Sadndya Agarwal, Ritu Agarwal et al (2014) compared the effects
adding dexmedetomidine 100µg to 0.325% of bupivacaine (30 ml) for
brachial plexus block by supraclavicular in 50 patients posted for upper
limb surgeries. The study design was a prospective, randomized,
double - blind, placebo-controlled trial. They found that
dexmedetomidine when added to bupivacaine for supraclavicular block
shortens the onset times for sensory and motor block and prolongs their
duration. The added advantage of conscious sedation, hemodynamic
stability and minimal side effects makes it a potential adjuvant for
nerve blocks.
9. F.W. Abdulla and R. Brull (2013)11, examined if perineural
dexmedetomidine used as a local anaesthetic adjuvant for central
neuraxial and peripheral nerve blocks can duration of analgesia be
extended as compared to local anaesthesia alone. A total of 516
patients were analysed from nine randomised controlled trials. Five
trials investigated dexmedetomidine as part of spinal anaesthesia and
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four as part of a brachial plexus block. Sensory block duration was
prolonged by 150 minutes with intrathecal dexmedetomidine.
Perineural dexmedetomidine may prolong the mean duration of
sensory block by 284 minutes. Motor block duration and time to first
analgesic request were prolonged for both intrathecal and brachial
plexus block. Dexmedetomidine produced reversible brachial plexus
block in 7% of brachial plexus block patients, but no effect on the
incidence of hypotension.
10. Marhofer D, Kettner SC et al (2013)14, evaluated dexmedetomidine as
an additive agent to ropivacaine in peripheral nerve blockade.
Profound prolongation of ulnar nerve block was detected with
perineural dexmeditomidine when added to 0.75% ropivacaine.
11. EL Saied et al (2000)15, Conducted study in which axillary brachial
plexus blockade was performed in 50 patients using 40ml ropivacaine
0.75%. Group (A) had 150µg clonidine and Group (B) 1ml normal
saline added to the local anaesthetic. There was no difference in onset
of sensory motor blockade. They concluded that the addition of 150µg
of clonidine to ropivacaine for brachial plexus blockade prolongs
motor and sensory block and analgesia without an increased incidence
of side effects.
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12. Klein SM, Greengrass RA et al. (1998), compared 30ml of 0.5%
bupivacaine, 0.5% ropivacaine and 0.75% ropivacaine for interscalene
brachial plexus block in 75 adult patients. Main purpose of this study
was to determine the concentration and ideal long acting local
anaesthetic drugs for interscalene brachial plexus block. The mean
onset time of both motor and sensory blockade was <6 minutes in all
groups. Duration of sensory block was similar in all groups. They
concluded that there was no clinically important difference in times to
onset and recovery of interscalene block for bupivacaine 0.5%,
ropivacaine 0.5% and ropivacaine 0.75% when injected in equal
volumes. Improvement in the time of onset or duration of analgesia of
interscalene brachial plexus block cannot be achieved by increasing the
concentration from 0.5% to 0.75% of ropivacaine.
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MATERIALS AND METHODS
This study was carried out in the orthopedic surgery, Government
Kilpauk Medical College and Hospital, Chennai after obtaining Institutional
Ethical Committee approval.
Study design
This study designed as a prospective, randomized, double blind,
comparative study. The local anesthetic solution prepared by an
anesthesiologist who was not involved in administration of block and post-
operative follow up. The anesthesiologist performing the block   and
observing the patient was blinded to the treatment group. The study may be
unblinded at any point of time if any complications occurred for benefit of
the patient.
Patient selection
The fifty adult patients both sexes age group of 20-60 years belonging
to ASA I and II category and their weight ranging between 50-70 kgs of
various types  upper limb orthopedic elective surgeries under ultrasound
guided brachial plexus block by supraclavicular approach who fulfill
inclusion criteria were enrolled in this study.
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Group selection
The patients were randomly assigned using “slips in the box
technique” to either of the following groups.
Group R: 25 patients received 30 ml 0f 0.5% Ropivacaine+1ml saline.
Group RD: 25 patients received 30ml of 0.5% Ropivacaine+1ml (1/2ml of
                     Dexmedetomidine with 1/2 ml of saline)
Inclusion criteria
? ASA I and II
? 20 – 60 years
? Both sexes
? Weight 50 – 70 kilograms
? Mid humerus, Elbow, Forearm and Hand surgeries
        Exclusion criteria
? Patient refusal
? Coagulopathy
? ASA III and above
? H/O severe cardiovascular, pulmonary, kidney, liver disease
? neurological, psychiatric, neuromuscular disorders
?  Infection / Sepsis / Allergy
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? Pneumothorax
? Peripheral Neuropathy
Materials
? Sterile tray for regional block
? Sterile towel with gauze, 20 ml syringe, 10 ml syringe, 2ml
syringe
? Drugs for the block 0.5 % Ropivacaine 30 ml, dexmedetomidine
50 mcg
? 22 G, 50mm short bevel insulated stimulating needle
? Ultra sound machine with high frequency (10-15 MHz) linear
probe
? Equipment’s and drugs for   resuscitation.
? Equipment’s and drugs for conversion to general anesthesia in
the case of block failure.
Monitoring
? Pulse oximetry
? Noninvasive blood pressure
? Electrocardiogram
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Methodology
 Pre-operative preparation
All Patients were pre-operatively evaluated, clinically examined and
proper investigations were done prior to assessment. Procedures were
explained to the patient and informed consent was obtained. They were
assessed with particular attention to any contraindications. Before the
procedure VAS (Visual Analogue Scale) on 0-10cm was clearly explained to
the patient for the assessment of post-operative pain. In this scale
i. 0 - indicate no pain
ii. 10 - indicate worst pain
Preoperative night patient was given with Tab. Alprazolam 0.5mg and
Tab. Ranitidine 150 mg.
Conduct of anesthesia
On arrival of the patient in the operation room, preprocedure
parameters blood pressure, heart rate and oxygen saturation were recorded
and noted. In the opposite limb an intravenous access was obtained with 18G
cannula and Ringer’s lactate was started.
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Positioning
The Patients was positioned supine with arm placed by the side. The
head was turned facing 45º to the contralateral side to be blocked.
Scanning Technique, Nerve Localization and Needle Placement
The neck was cleaned with povidone iodine solution and draped with
sterile towels. The anesthesiologist stands at the head end of the patient.
Sterile gel was used between the probe and skin surface. In the coronal
oblique plane the probe was kept in the supraclavicular fossa.
The pulsating hypo echoic subclavian artery was identified and
confirmed by colour Doppler, lying above the hyper echoic first rib. While
maintaining the view of the artery the probe was angled until both the first rib
and the pleura were seen simultaneously to visualize these two structures.
Once the artery, rib, pleura and plexus were simultaneously in view the
aim was to guide the needle inferior to the first rib, medial to the subclavian
artery and superior to the nerves. In this area the lower trunk commonly lies.
After local skin infiltration, the needle was entered by in - plane from lateral
to medial until brachial plexus was reached. The supraclavicular brachial
plexus was visualized as a group of hypo echoic nodules. The local anesthetic
solution was injected after careful aspiration and spread was seen encircling
the trunks. After   injecting the local anaesthetic the block was tested for both
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sensory (using pin prick) and motor (using muscle power) and was compared
with the contralateral side.
Evaluation of the block
Sensory block was evaluated using 3-point scale by the pin prick
method. After injecting the local anesthetic drug the sensory block was
assessed at every minute in the dermatome areas corresponding to Median
nerve, Radial nerve, ulnar nerve and Musculocutaneous nerve until the
completion of sensory blockade.
Onset of sensory block means - Dull sensation to pin prick along the nerve
distribution. (Grade-1)
 Completion of sensory block means - Complete loss of sensation to pin
prick. (Grade-2)
Grade  Sensory  block
0 Sharp  pin felt
1 Analgesia ,  dull  sensation
2 Complete Anaesthesia,
absence of  sensation
Evaluation of motor block was done at every minute till complete
motor blockade after the drug injection.
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Evaluation of motor block done by
? Thumb  abduction (Radial  nerve)
? Thumb adduction (Ulnar  nerve)
? Thumb  opposition  (Median  nerve)
? Flexion of the elbow, supination and pronation of the forearm
(Musculocutaneous)
Onset of motor blockade means Grade -1.
Peak motor block means Grade- 2.
Modified Bromage scale
This scale assessed the motor block for upper limb on a 3-point scale.
Grade                          Motor blockade
0 Full   flexion, extension of elbow, wrist and fingers, Normal.
1 Decreased motor power, can able to move the fingers only.
2 Inability to move the fingers, Complete block.
Incomplete block referred to - No analgesia in any of the segments
supplied by Median, Radial, Ulnar and Musculocutaneous nerve after 30
minutes of drug injection.
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Failed block - More than one nerve remained unaffected.
In this situation, general anesthesia was considered and not included
for study.
Hemodynamic monitoring was done such as heart rate, blood pressure
and oxygen saturation continuously throughout the surgery and every 60
minutes post - operative period.
Sedation of patient was assessed by the Ramsay Sedation Scale.
Score Definition
1 Patient anxious and agitated or restless or both
2 Patient cooperative, oriented and tranquil
3 Patient responds to commands only
4 Patient has a brisk response to a light glabellar tap or loud
auditory stimulus
5 Patient asleep, sluggish response to light glabellar tap or loud
auditory stimulus
6 Patient doesn’t respond to painful stimulus
Assessment of blood loss was done and fluid was administered as per
the loss. Duration of surgery was noted.
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Patients were assessed for duration of analgesia as per Visual
Analogue Scale.  After the surgery it was monitored every 1 hour until the
score reaches - 5. The rescue analgesia was given with parental use of
Diclofenac injection when the VAS reaches 5 and the time of the injection
was recorded.
All patients were observed for any side-effects like nausea, vomiting,
dryness of mouth and complications like pneumothorax, hematoma, local
anesthetic toxicity and post - block neuropathy in the intra - and post-
operative periods. The patient was requested to note the subjective resolution
of sensation and movements. Finally it was counter checked by the
anesthesiologists.
Time interval between the completion of local anaesthetic solution
administration and the complete resolution of anaesthesia on all nerves was
considered as the duration of sensory block (grade0).
The time interval between the completion of local anaesthetic
administration and the recovery of complete motor function of the hand and
forearm was considered as the duration of motor block (grade 0).
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VISUAL ANALOG SCALE
Ultrasound machine with linear transducer – Imaging the
supraclavicular brachial plexus by an in-plane technique
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 22 Gauge Short bevel insulated stimulating needle
                                                   Drugs
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Statistical Analysis
All the data were subjected to statistical significant estimation.
The parameters of age, weight, total time taken for surgery, heart rate,
blood pressure, oxygen saturation, time taken for sensory and motor
blockade, offset time for sensory and motor blockade and total time of
analgesia were analyzed by Independent t-test. Chi-square test was used for
sex and ASA. A P-value less than 0.05 were considered statistically
significant.
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OBSERVATION AND RESULTS
There was no statistically significant difference between the
demographic data (age, Sex, weight) and ASA grade, duration of surgery.
Parameters R Group RD Group T value P value
Age (Years)
Mean 33.64 33.70 -0.033 0.974
SE 1.68 1.73
Weight (kg)
Mean 69.16 69.16 0.00 1.00
SE 4.35 4.35
Gender
Male 16 18 0.37 0.544
Female 9 7
The mean age of the subjects in R group was 33.64 years and it was 33.7
years in RD group.
P value- 0.794           :      Not statistically significant.
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ASA Physical Status
Parameters R Group RD Group Chi square P value
ASA
I 22 21 0.17 0.683
II 3 4
DURATION OF SURGERY
Duration of
surgery (min)
R Group RD Group T value P value
Mean 162.0 162.0 0.00 1.00
SE 3.74 3.21
There were no statistically significant values observed in ASA physical status
and duration of surgery in both the groups.
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ONSET OF SENSORY BLOCK
Onset of sensory
(minutes)
R Group RD Group T value P value
Mean 9.2 6.8 12.0 0.001
SE 0.15 0.13
The mean onset of sensory block was 9.2 minutes in R group compared
to 6.8 minutes in the RD group. This difference in means was found to be
statistically significant.
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ONSET OF MOTOR BLOCK
Onset of motor
(min)
R Group RD Group T value P value
Mean 13.12 9.0 18.232 0.001
SE 0.18 0.14
The mean onset time of motor block was 13.12 minutes in R group
compared to 9.0 minutes in the RD group. This difference in means was
found to be statistically significant.
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DURATION OF   SENSORY BLOCK
Duration of
sensory  (minutes)
R Group RD Group T value P value
Mean 506.2 709.0 -26.547 0.001
SE 3.71 6.68
The sensory block duration (mean) of the subjects in group R was
506.2  minutes and it was 709 minutes in RD group.
P value - 0.001                      :                statistically significant.
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DURATION  OF   MOTOR  BLOCK
Duration of
motor (min)
R Group RD Group T value P value
Mean 478.8 669.2 -34.199 0.001
SE 3.74 4.12
The motor duration (mean) of block of the subjects in group R was
478.8 minutes and it was 669.2 minutes in RD group.
 P value -0.001                       :        statistically significant.
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DURATION OF ANALGESIA
Analgesia duration
(minutes)
R Group RD Group T value P value
Mean 568.20 831.80 -34.998 0.001
SE 3.15 6.84
The analgesia duration (mean) of group R was 568.2 minutes whereas
it was 831.8 minutes among subjects of RD group. This difference is found to
be statistically significant.
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RESCUE ANALGESIA
Rescue analgesia
(minutes)
R Group RD Group T value P value
Mean 588.00 850.40 -34.682 0.001
SE 2.92 6.98
The mean time of rescue analgesia was found to be 588 minutes among
subjects in group R, while the mean time of rescue analgesia was 850.4
minutes among RD group subjects.
 P value-0.001                          :        statistically significant.
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VISUAL ANALOG SCALE
Parameters R Group RD Group T value P value
VAS  6 hours
Mean 0.24 0 2.753 0.011
SE 0.09 0
VAS 10 hours
Mean 4.36 0.16 30.851 0.001
SE 0.1 0.09
VAS 14 hours
Mean 6.36 4.12 18.931 0.001
SE 0.1 0.07
VAS 18 hours
Mean 8.36 5.96 17.955 0.001
SE 0.1 0.09
VAS 24 hours
Mean 10 8.24 13.266 0.001
SE 0 0.13
The mean VAS of the R group when compared to RD group at 6, 10,
14, 18 and 24 hours were found to be statistically significant.
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OBSERVATION OF HAEMODYNAMIC VARIABLES
Parameters R Group RD Group T value P value
HR 0 min
Mean 92.96 93.4 -0.877 0.385
SE 0.39 0.32
SBP 0 min
Mean 131.52 131.52 0 1
SE 0.49 0.49
DBP 0 min
Mean 88.8 88.64 0.142 0.887
SE 0.79 0.8
SpO2 0 min
Mean 99.8 99.84 -0.361 0.72
SE 0.08 0.07
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Parameters R Group RD Group T value P value
HR 15 min
Mean 85.28 76.56 10.855 0.001
SE 0.38 0.71
SBP 15 min
Mean 130 125.36 7.25 0.001
SE 0.5 0.4
DBP 15 min
Mean 84.64 74.72 14.399 0.001
SE 0.47 0.5
SpO2
15 min
Mean 99.76 99.8 -0.335 0.739
SE 0.09 0.08
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Parameters R Group RD Group T value P value
HR 30 min
Mean 83.84 70 23.101 0.001
SE 0.32 0.5
SBP 30 min
Mean 129.04 107.84 31.016 0.001
SE 0.61 0.3
DBP 30 min
Mean 83.84 68.48 32.074 0.001
SE 0.42 0.24
SpO2 30 min
Mean 99.76 99.84 -0.696 0.49
SE 0.09 0.07
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Parameters R Group RD Group T value P value
HR 60 min
Mean 83.6 66.48 30.089 0.001
SE 0.38 0.42
SBP 60 min
Mean 128.96 105.84 43.651 0.001
SE 0.46 0.26
DBP 60 min
Mean 83.44 66.64 47.863 0.001
SE 0.29 0.19
SpO2 60 min
Mean 99.76 99.84 -0.696 0.49
SE 0.09 0.07
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Parameters R Group RD Group T value P value
HR 120 min
Mean 83.28 63.92 29.94 0.001
SE 0.36 0.54
SBP 120 min
Mean 128.32 104.96 39.828 0.001
SE 0.53 0.26
DBP 120 min
Mean 82.16 65.92 45.873 0.001
SE 0.23 0.27
SpO2 120
min
Mean 99.84 99.88 -0.4 0.691
SE 0.07 0.07
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Parameters R Group RD Group T value P value
HR 180 min
Mean 82.48 62.72 39.095 0.001
SE 0.39 0.32
SBP 180
min
Mean 127.92 106 41.948 0.001
SE 0.47 0.23
DBP 180
min
Mean 82 65.2 31.749 0.001
SE 0.28 0.45
SpO2 180
min
Mean 99.8 99.92 -0.463 0.646
SE 0.07 0.06
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Parameters R Group RD Group T value P value
HR 240 min
Mean 82.32 62.16 30.578 0.001
SE 0.47 0.46
SBP 240 min
Mean 127.6 106.96 36.396 0.001
SE 0.53 0.2
DBP 240 min
Mean 81.76 67.2 43.715 0.001
SE 0.27 0.2
SpO2 240 min
Mean 99.8 99.92 -1.216 0.231
SE 0.08 0.06
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Parameters R Group RD Group T value P value
HR 300 min
Mean 81.84 64.48 43.043 0.001
SE 0.32 0.24
SBP 300 min
Mean 127.6 108.24 41.503 0.001
SE 0.48 0.13
DBP 300 min
Mean 81.68 67.6 39.192 0.001
SE 0.28 0.23
SpO2
300 min
Mean 99.8 99.92 -1.216 0.231
SE 0.08 0.06
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Trend line of Heart rate in both the groups
89
Trend line of systolic BP among the study subjects
90
Trend line of diastolic BP among the study subjects
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SEDATION SCORES
Parameters R Group RD Group T value P value
Sedation score
1 hour
Mean 1.00 2.12 -16.885 0.001
SE 0.00 0.07
Sedation score 2
hours
Mean 1.00 2.12 -16.885 0.001
SE 0.00 0.07
Sedation score
3 hours
Mean 1.00 2.12 -16.885 0.001
SE 0.00 0.07
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The sedation score (mean) among the subjects in R group was 1 and
the mean sedation score in group RD was 2.12 respectively. The difference
was found to be statistically significant.
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DISCUSSION
This prospective randomized double blind study was done in patients
undergoing elective upper limb orthopaedic surgery under supraclavicular
brachial plexus block.
Brachial plexus blockade provide an excellent alternative technique to
general anaesthesia for upper limb surgical procedures. It not only offers
excellent intraoperative pain relief but also good post-operative analgesia.
Supraclavilar technique was chosen for this study because it provides a rapid
onset, dense and predictable anaesthesia with high success rate.
Technique
In this study we used ultra sound guided supraclavicular blocks. This
technique allows the direct visualisation of nerves and anatomical structures.
Avoidance of complication and reduce the dose of local anaesthetic agents.
M.S. Abrahams et al1 concluded that ultra sound improves the quality
of blockade when compared to methods that use the peripheral nerve
stimulator for nerve identification.
Vincent W.S.Chan et al2 conducted a study in 188 patients and
demonstrated that axillary brachial plexus block significantly improved the
success rate under the guidance of ultrasound with or without nerve
stimulation.
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Hickey et al7 studied subclavian perivascular brachial plexus block
using 30 ml of 0.5% ropivacaine under elicitation of paraesthesia technique
for localisation of nerve. They found that the peak onset of sensory blockade
was 28 minutes.  In this study the peak onset of sensory blockade was 9.2
minutes. The difference may be due to difference in technique used for the
localisation of brachial plexus. They used elicitation of paraesthesia for
localisation of nerve plexus, which was not as accurate as use of ultra sound
in our study.
Drugs
Ropivacaine is a long - acting regional anaesthetic that is structurally
related to bupivacaine. It is a pure S (-) enantiomer, unlike bupivacaine. It
developed for the purpose of reducing potential toxicity and improving
relative sensory and motor block profiles. Ropivacaine has lower lipid
solubility and have produced less central nervous system and cardiac toxicity
than bupivacaine for which it is gaining popularity over bupivacaine for
peripheral neural blockade when large volumes of local anesthetic are
required. Ropivacaine is also used in the chronic pain management.
Ropivacaine is as effective as bupivacaine and levobupivacaine when
used in peripheral nerve blocks. But it is less potent than bupivacaine when
used in epidural or Intrathecal route. Clinically adequate doses of ropivacaine
appear to be associated with a lower grade of motor block than bupivacaine.
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Ropivacaine is considered as an important option for regional anaesthesia,
postoperative pain management and labour analgesia due to the following
reasons:
? Efficacy
? Lower propensity for motor block.
? Reduced potential for central nervous system toxicity and cardio
toxicity.
In our study, the mean onset time of sensory and motor was quicker in
group RD. The mean duration of sensory (709 minutes), motor (669.2
minutes) in group RD, whereas in group R the mean duration of sensory (506
minutes), motor (478.8 minutes). The duration of analgesia was extended in
Ropivacaine Dexmedetomidine group than in Ropivacaine group.
El Saied et al15 concluded that the adding additives like clonidine (150
µg) to ropivacaine for brachial plexus blockade extends the duration of
sensorimotor  and that of analgesia without any side effects.
Klein et al18 compared the efficacy of bupivacaine 0.5% and different
concentration of ropivacaine 0.5%, ropivacaine 0.75%. They used 30ml in
each group. They explored that there wasn’t any significant difference in time
of onset and recovery. On increasing the concentration from 0.5% to 0.75%
of ropivacaine, it did not show any improvement in the onset or duration of
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analgesia. In this study, we used 0.5% of ropivacaine 30ml which was similar
to Klein et al study.
Post-operative analgesia can be extended by continuous catheter based
technique. But it needs extra time, skill, cost and catheter related
complications.
 Pharmacologically active d-isomer of medetomidine is known as
Dexmedetomidine16.It is more selective towards ?-2 adrenoceptor agonist
with ?-2:?-1 binding selectivity ratio of 1620:1 and decreasing the unwanted
side effect of ?-1 receptors. High selectivity for ?-2 receptors mediates
analgesia, sedation and anxiolysis.
Memis12 and colleagues first proposed dexmeditomidine, ?-2
adrenoreceptor agonist when used as an additive agent to local anaesthetics
with an ability of prolonging the sensory and motor block duration.
Esmaoglu5 et al. added dexmedetomidine to levobupivacaine for
axillary brachial plexus block and showed that it shortens the time taken for
onset of sensorimotor block and prolongs the time of blockade and that of
post-operative analgesia.
A study by Obayah13 and colleagues during greater palatine nerve
block for cleft palate surgery added an adjuvant dexmedetomidine to
bupivacaine solution. When bupivacaine mixed with dexmedetomidine
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provided lower pain scores and prolonged analgesia with no negative effects
on hemodynamics when compared to bupivacaine alone.
Several animal studies have investigated the analgesic effects of
dexmeditomidine as an adjuvant. A study by Brumett8 et al. showed that
when dexmeditomidine used with bupivacaine, increases the duration of
bupivacaine anaesthesia and analgesia of sciatic nerve block in rats without
any damage to the nerve.
The above studies show that selective ?2  – adrenoceptor agonist like
clonidine or dexmedetomidine when added as adjuvant to ropivacaine in
different peripheral nerve block potentiates the sensorimotor blockade.
The mechanism of action is probably due to
? The peripheral action of ?2 agonists produce analgesia by decreasing
the  norepinephrine release, leading to ?2 - receptor independent
inhibitory effects on nerve fibre action potentials.
? The central action of ?2 agonists produces sedation and analgesia by
inhibition of substance P release in the nociceptive pathway.
? Also by activation of ?2 – adrenoceptors in locus coeruleus.
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Therefore, the dexmedetomidine action via a simillar mechanism of action
when added with the local anesthetic solutions leading to a long lasting
action.
Adding adjuvant like dexmeditomidine to ropivacaine prolonging the
analgesia with one shot block can result in a longer time of post - operative
analgesia and can avoid continuous catheterization.
The added advantage of conscious sedation, hemodynamic stability
and the lack of significant side effects like respiratory depression make
Dexmedetomidine better choice as an adjuvant for supraclavicular brachial
plexus block.
None of the patients in group RD required sedation intra - operatively.
They were comfortable throughout the surgery with arousable sedative effect.
This is due to partial vascular uptake of the drug and its transport to the
central nervous system. As ?2 agonists produce sedation by central action
and in the nociceptic pathway at the level of dorsal root neuron causes
substance P release inhibition and in the locus coerelus ?2 adrenoceptor
activation. The limited duration of sedation could be explained by the fact
that it is highly lipophilic and diffuses faster in to the blood vessels by rapid
clearance and short half-life. In our study, the highest sedation score was 3.
No patient required airway assistance due to sedation.
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Haemodynamic variables like heart rate, blood pressure, oxygen
saturation was significantly low in group RD from the 15th minutes of the
onset of blockade. They were stable throughout the surgery.
 Only two patients had heart rate <60/min. But no patient required
Inj.Atropine or vasopressor support. The hypotension was only mild and
corrected with intravenous crystalloids.
No complications were observed.
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SUMMARY
On comparing Ropivacaine 0.5% and Ropivacaine 0.5% with
dexmedetomidine 50µg in Ultrasound Guided Supraclavicular Brachial
plexus Block for Upper limb Orthopedic Surgery the following findings were
observed.
1. Onset of sensory and motor blockade was quicker in group RD
(Ropivacaine with Dexmedetomidine) when compared to group R
(Ropivacaine).
2. The mean duration of the sensory and motor blockade was
significantly prolonged in group RD (Ropivacaine with
Dexmedetomidine).
3. The mean duration of analgesia was significantly prolonged in group
RD (Ropivacaine with Dexmedetomidine).
4. Rescue analgesia was needed earlier in group R (Ropivacaine) than
that of group RD (Ropivacaine with Dexmedetomidine).
5. Hemodynamic parameters were significantly low from 15th minutes
after the onset of blockade in group RD (Ropivacaine with
Dexmedetomidine) than in group R (Ropivacaine).
6. Sedation was statistically significant in group RD (Ropivacaine with
Dexmedetomidine) in the intraoperative period.
7. There was no complication seen in both the groups during the study.
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CONCLUSION
In conclusion, Dexmedetomidine 50µg when added as an adjuvant to
Ropivacaine 0.5% for supraclavicular brachial plexus block hastens the onset
of sensory and motor blockade and prolongs the duration of sensorimotor
blockade and provides a longer pain - free period when compared to
Ropivacaine alone.
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PROFORMA
Name:       Age/Sex: Wt: ASA Status:
IP No:       Surgery:                         Duration of Surgery:
Group R/RD:
Preoperative examination
PR:    BP: SPO2: CVS: RS: Airway:
Investigation: Hb:            BT:   CT:
Onset of block Sensory: Motor:
Completion of block Sensory: Motor:
Duration of Analgesia
0
min
5
min
10
min
15
Min
20
min
30
min
1
hr
2
hr
3
hr
4
hr
5
hr
6
hr
12
hr
24
hr
Vital PR
BP
RR
SpO2
Sens&Motor Score
Radial
Nerve
S
M
Median
Nerve
S
M
Ulnar
Nerve
S
M
Musculocut.
Nerve
S
M
Sedation
Score
Baseline 30 mins 60 mins 90 mins 120
min
180
min
240
min
Time of
Rescue
analgesia/
Post op.
1 hr 2 hrs 3 hrs 4 hrs 5 hrs 6 hrs
Complication:
S. No 0 min 15 mins 30 mins 60 min 120 mins 180 mins 240 min 300 mins
HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2
1 90 136 90 100 88 136 90 100 88 138 90 99 90 136 88 99 90 136 84 100 90 134 86 100 92 134 84 100 86 132 82 99
2 92 134 90 100 86 134 88 100 82 136 88 99 88 134 86 100 86 134 84 100 84 134 84 100 86 134 84 99 86 132 82 100
3 90 132 92 99 88 130 86 99 84 134 86 100 82 132 84 100 84 132 84 100 84 132 84 100 84 134 84 100 84 132 82 100
4 91 130 88 100 86 128 84 100 82 128 84 100 82 130 82 100 82 130 82 100 82 130 82 100 82 130 84 100 82 132 82 100
5 93 130 90 100 86 128 82 99 84 128 82 100 82 130 84 100 84 130 84 99 82 128 82 100 82 126 82 100 82 128 82 100
6 91 128 92 100 84 126 84 99 86 126 84 100 84 128 84 99 84 126 82 100 82 128 82 100 82 128 82 99 82 126 84 99
7 92 130 94 100 84 130 86 100 82 128 84 100 82 130 84 99 82 128 82 100 82 126 82 100 82 128 82 100 80 126 84 100
8 96 134 90 100 86 132 88 100 84 130 86 100 84 128 84 100 82 126 82 100 80 126 82 100 80 126 82 100 80 126 84 100
9 94 132 92 100 86 130 82 100 84 128 82 99 84 128 82 100 82 126 82 100 82 126 82 100 82 128 80 99 80 126 84 99
10 93 136 86 99 84 132 82 100 84 130 82 100 82 130 82 100 82 128 80 100 82 126 84 100 80 126 82 100 82 128 82 100
11 94 128 84 100 86 126 82 100 84 126 84 100 84 128 84 100 84 126 82 100 82 128 82 99 82 126 82 100 82 128 80 100
12 91 130 80 100 88 128 84 99 86 130 84 99 84 128 84 100 84 128 82 100 84 126 80 99 82 126 80 100 82 128 80 100
13 95 134 82 100 84 132 86 100 82 126 84 100 82 128 82 99 82 128 82 100 80 126 80 100 82 126 82 100 82 126 80 100
14 94 128 80 100 86 126 86 100 84 126 82 100 84 130 84 100 82 128 82 100 82 128 82 100 80 128 82 100 82 126 82 100
15 93 130 86 100 84 128 84 100 86 128 82 100 84 130 84 99 82 130 82 100 82 126 82 100 82 126 82 100 82 126 82 100
16 90 132 90 100 84 130 86 100 82 128 84 100 82 128 82 100 84 130 84 100 82 128 82 100 82 126 82 100 82 126 82 100
17 91 134 92 100 88 132 82 99 84 130 82 100 84 128 82 100 82 128 82 100 84 128 82 100 82 126 82 100 80 126 82 100
18 92 130 90 99 86 130 82 100 84 128 82 99 84 126 84 100 84 126 80 100 82 126 82 100 82 126 80 100 80 130 80 100
19 94 132 92 100 84 132 86 100 82 130 84 100 82 128 82 100 82 126 82 100 82 128 80 100 82 128 80 99 80 128 80 100
20 95 130 86 100 84 128 84 100 84 126 82 100 84 128 82 100 84 128 82 100 82 128 80 100 80 126 80 100 82 126 80 99
21 96 134 90 100 82 132 82 100 84 128 82 100 82 126 82 100 82 126 82 100 82 128 82 100 82 126 82 100 82 126 80 100
22 92 128 88 99 82 130 84 99 84 130 82 100 84 128 84 99 82 128 82 99 84 126 82 99 82 126 82 100 82 126 82 100
23 94 130 90 100 86 128 86 100 82 126 84 100 84 126 84 100 84 126 82 99 82 128 82 100 82 126 82 99 82 126 82 100
24 96 132 92 99 88 130 82 100 86 128 86 100 82 128 82 100 84 128 80 99 82 126 82 100 82 126 80 100 82 126 82 100
25 95 134 94 100 82 132 88 100 82 130 84 99 84 128 84 100 82 126 82 100 80 128 80 100 82 128 80 100 80 128 80 99
GROUP - R (Ropivacaine)
S. No 0 min 15 mins 30 mins 60 min 120 mins 180 mins 240 min 300 mins
HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2 HR SBP DBP SPO2
1 94 136 90 100 82 126 80 100 76 110 70 100 70 108 68 99 66 108 68 100 66 106 68 100 64 106 68 99 66 108 66 100
2 92 134 90 100 84 124 78 100 74 110 68 100 70 108 68 100 68 106 68 99 66 106 68 100 64 106 68 100 66 108 66 100
3 92 132 92 100 82 126 78 99 74 110 70 100 70 108 68 100 66 106 68 100 66 106 68 100 66 106 68 100 66 108 66 100
4 92 130 90 100 76 128 78 100 74 110 70 99 70 108 68 99 68 106 68 100 64 106 68 99 66 106 68 100 66 108 68 100
5 93 130 92 100 80 128 78 99 74 108 70 100 68 106 68 100 66 106 68 100 64 106 68 100 66 106 66 100 66 108 66 100
6 91 128 92 99 80 126 76 100 70 108 68 100 68 106 66 100 66 106 66 100 64 106 68 100 66 108 68 100 66 108 66 100
7 92 130 94 100 78 124 76 100 70 108 68 100 68 106 66 99 66 106 66 100 64 106 66 100 66 108 68 100 66 108 66 100
8 96 134 90 100 78 124 76 100 70 108 68 100 68 106 66 100 58 106 66 100 62 106 66 100 62 108 68 100 66 110 70 99
9 95 132 92 100 78 124 76 99 70 108 68 99 68 104 66 100 66 104 66 100 62 108 66 100 62 108 68 100 64 108 68 100
10 93 136 88 99 78 124 76 100 70 108 68 100 66 106 66 100 66 104 66 100 62 108 66 100 62 108 68 100 64 108 68 100
11 94 128 82 100 76 124 74 100 68 110 70 100 66 106 66 100 66 104 66 100 62 108 66 100 62 108 68 100 64 108 68 100
12 91 130 80 100 76 128 76 99 68 110 70 100 66 106 66 100 64 104 66 100 62 108 64 100 60 108 68 100 64 108 68 100
13 95 134 82 100 76 126 74 100 68 108 70 100 66 106 66 100 64 104 66 100 60 106 64 100 60 106 66 100 64 108 68 100
14 95 128 80 100 74 126 74 100 68 106 70 99 66 106 68 100 64 104 66 100 62 106 64 100 60 106 66 100 64 110 70 100
15 93 130 86 100 74 126 74 100 68 106 68 100 66 104 66 99 64 104 66 100 62 106 64 100 60 106 66 100 64 108 68 100
16 92 132 86 100 74 126 74 100 70 106 68 100 64 104 66 100 58 104 66 100 62 106 64 100 60 106 66 100 64 108 68 100
17 91 134 88 100 74 126 74 99 70 106 68 100 64 104 66 100 64 104 66 100 62 106 66 100 60 106 68 100 62 108 68 100
18 92 130 90 99 74 124 72 100 70 108 68 100 64 104 66 100 64 104 66 100 62 106 66 100 60 106 68 100 64 108 68 100
19 93 132 92 100 74 122 72 100 70 108 66 100 64 104 66 100 64 104 66 100 62 106 60 99 60 106 68 100 64 108 68 99
20 95 130 88 100 72 128 72 100 70 108 68 100 64 106 66 100 62 102 64 100 64 106 60 100 62 108 68 100 64 108 68 100
21 94 134 90 100 72 126 74 100 68 108 68 100 64 106 66 100 62 106 64 100 62 104 64 100 62 108 66 100 64 108 68 100
22 94 128 88 99 72 126 72 100 68 106 68 100 66 106 66 100 62 106 64 99 62 104 64 100 62 108 66 100 64 108 68 100
23 95 130 90 100 72 128 72 100 68 106 68 100 66 106 68 100 62 106 64 100 62 104 64 100 62 108 66 100 64 110 68 100
24 96 132 90 100 76 120 72 100 68 106 68 100 66 106 68 100 62 106 64 99 62 104 64 100 60 108 66 100 64 108 68 100
25 95 134 94 100 82 124 70 100 66 106 66 99 64 106 66 100 60 104 64 100 60 106 64 100 60 106 66 99 62 108 66 100
GROUP - RD (Ropivacaine with Dexmedetomidine)
S. No Age Sex Wt. ASA DOS On.sen On.mot DO.sen DO.mot DOA Res. An. 6 h 10 h 14 h 18 h 24 h 1 hr 2 hr 3 hr S/E
1 25 f 70 II 110 9 12 480 460 560 580 0 4 6 8 10 1 1 1 nil
2 28 f 74 I 170 10 13 495 475 580 600 1 5 6 8 10 1 1 1 nil
3 26 m 78 I 130 8 11 510 485 570 580 0 5 7 9 10 1 1 1 nil
4 30 f 68 I 190 10 14 525 500 570 590 0 4 6 8 10 1 1 1 nil
5 32 m 64 I 170 8 14 470 450 550 570 0 4 7 9 10 1 1 1 nil
6 34 f 66 I 160 10 14 490 460 570 590 0 4 6 8 10 1 1 1 nil
7 36 m 62 I 190 9 13 515 485 560 580 0 4 6 8 10 1 1 1 nil
8 52 m 62 I 170 9 13 520 495 580 600 1 5 7 9 10 1 1 1 nil
9 45 m 67 II 170 9 13 535 500 580 600 1 5 6 8 10 1 1 1 nil
10 38 m 68 I 140 8 12 485 445 570 590 0 4 6 8 10 1 1 1 nil
11 24 f 64 I 150 10 14 490 470 580 600 0 4 6 8 10 1 1 1 nil
12 26 f 68 I 160 10 14 505 485 580 600 0 4 6 9 10 1 1 1 nil
13 28 m 70 I 180 8 12 515 495 570 590 0 4 7 9 10 1 1 1 nil
14 30 f 72 I 190 9 12 520 495 600 620 1 5 6 8 10 1 1 1 nil
15 32 f 74 I 160 9 13 535 500 600 615 1 5 6 8 10 1 1 1 nil
16 53 m 68 I 170 9 13 540 520 580 595 0 4 7 9 10 1 1 1 nil
17 46 m 70 I 180 10 14 515 495 540 560 0 4 7 9 10 1 1 1 nil
18 42 m 72 II 160 10 14 485 450 550 575 0 4 6 8 10 1 1 1 nil
19 28 m 77 I 180 8 12 490 470 550 575 0 5 7 9 10 1 1 1 nil
20 24 m 76 I 150 9 13 510 480 570 590 0 4 6 8 10 1 1 1 nil
21 26 m 69 I 140 10 14 505 475 560 580 0 4 6 8 10 1 1 1 nil
22 28 f 68 I 150 10 14 500 470 560 580 0 4 7 8 10 1 1 1 nil
23 34 m 70 I 160 9 13 490 460 550 570 0 5 7 9 10 1 1 1 nil
24 38 m 68 I 170 9 13 505 470 545 570 0 4 6 8 10 1 1 1 nil
25 36 m 72 I 180 10 14 525 480 580 600 1 5 6 8 10 1 1 1 nil
GROUP - R (Ropivacaine)
VASMinutes Sed.scores
Sed. scores
S. No Age Sex Wt. ASA DOS On.sen On.mot DO.sen DO.mot DOA Res. An. 6 h 10 h 14 h 18 h 24 h 1 hr 2 hr 3 hr S/E
1 26 m 70 II 120 7 10 680 665 885 905 0 0 4 6 8 2 2 2 nil
2 27 f 74 I 180 7 10 710 680 850 870 0 0 4 6 8 2 2 2 nil
3 25 m 78 I 130 6 9 690 675 890 910 0 0 5 7 10 2 2 2 nil
4 29 f 68 I 180 6 9 720 695 840 860 0 0 4 6 8 2 2 2 nil
5 31 m 64 I 180 7 9 670 645 880 900 0 0 4 6 8 2 2 2 nil
6 32 f 66 I 170 6 8 695 670 825 840 0 0 4 6 8 2 2 2 nil
7 36 m 60 I 170 7 9 700 675 815 840 0 0 4 6 8 2 2 2 nil
8 54 m 62 I 180 7 9 685 635 875 895 0 0 4 6 8 3 3 3 nil
9 44 m 64 II 170 7 9 685 660 890 910 0 0 5 7 10 2 2 2 nil
10 39 m 68 I 150 7 10 690 665 795 810 0 1 4 6 8 2 2 2 nil
11 25 f 64 I 150 6 8 725 675 810 825 0 0 4 6 8 2 2 2 nil
12 25 f 68 I 160 6 8 760 680 815 830 0 0 4 6 8 3 3 3 nil
13 29 m 70 I 170 7 9 740 695 825 840 0 0 4 6 8 2 2 2 nil
14 29 m 72 I 180 7 9 680 655 795 810 0 0 4 6 8 2 2 2 nil
15 31 f 74 I 160 7 9 695 670 805 825 0 0 4 6 8 3 3 3 nil
16 54 m 68 II 160 7 9 785 685 815 840 0 0 4 6 8 2 2 2 nil
17 45 m 70 I 180 8 10 785 655 825 840 0 0 4 5 8 2 2 2 nil
18 43 m 72 II 150 8 10 720 690 825 840 0 0 4 5 8 2 2 2 nil
19 29 m 74 I 170 6 9 695 655 825 845 0 0 4 5 8 2 2 2 nil
20 25 m 76 I 160 7 9 745 645 890 910 0 0 5 6 8 2 2 2 nil
21 27 m 69 I 150 7 9 680 660 815 840 0 0 4 6 8 2 2 2 nil
22 29 f 68 I 140 7 10 670 695 835 845 0 0 4 6 8 2 2 2 nil
23 33 m 70 I 160 6 8 695 645 790 810 0 0 4 6 8 2 2 2 nil
24 39 m 68 I 160 6 8 740 720 790 810 0 1 4 6 8 2 2 2 nil
25 37 m 72 I 170 8 8 685 640 790 810 0 2 4 6 10 2 2 2 nil
GROUP - RD (Ropivacaine with Dexmedetomidine)
VASMinutes


PATIENT INFORMED CONSENT FORM
Study Detail     : “A Comparative Study of Ropivacaine 0.5% and
Ropivacaine 0.5% With Dexmedetomidine 50µg in
Ultrasound Guided Supraclavicular Brachial plexus Block
for Upper limb Orthopedic Surgery”.
Study Centre    : GOVT. KILPAUK  MEDICAL COLLEGE &
HOSPITAL, CHENNAI.
Patient’s Name  :
Patient’s Age      :
Identification
Number            :
                                 Patient may check (       ) these boxes
I confirm that I have understood the purpose of procedure for the
above study. I have the opportunity to ask question and all my
questions and doubts have been answered to my complete
satisfaction.
I understand that my participation in the study is voluntary and that I
am free to withdraw at any time without giving reason, without my
legal rights being affected.
I agree to take part in the above study and to comply with the
instructions given during the study and faithfully cooperate with the
study team and to immediately inform the study staff if I suffer from
any deterioration in my health or well-being or any unexpected or
unusual symptoms.
I hereby consent to participate in this study.
I hereby give permission to undergo complete clinical examination
and diagnostic tests including hematological, biochemical,
radiological tests.
Signature/thumb impression:
Patients Name and Address :                       Place: Date:
Signature of investigator  :
Study investigator’s Name  :                         Place: Date:
Consent form in regional language (Tamil)
